Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > New Hope for Patients Suffering from Degenerative, Inflammatory Eye Diseases

Abstract:
TheraKine and Capsulution Start Joint Development

New Hope for Patients Suffering from Degenerative, Inflammatory Eye Diseases

Berlin, Germany | Posted on October 1st, 2007

Capsulution NanoScience AG, a Berlin-based company, and TheraKine Ltd., an Irish company with significant operations in the United States, are establishing a joint project for the treatment of serious eye diseases. Their aim is to develop an innovative drug-delivery system for ophthalmic applications which will enable local sustained release of one or multiple anti-inflammatory and anti-proliferative biologic and small molecule compounds. This will allow the therapy of difficult to treat eye diseases such as uveitis, diabetic retinopathy and age-related macular degeneration (AMD).

The current treatment possibilities for inflammation of the eye are more than unsatisfactory. Steroids and immunosuppressants have many severe side effects and limited efficacy. Biologic compounds need regularly repeated intravenously or intravitreal injections at relatively high doses. When administered systemically, only traces of the compound reach the interior of the eye, but cause undesirable side effects due to high levels of the compound in other parts of the body. Intravitreal injections offer a solution to this; but currently these still require repeated injections and are limited to a small number of anti-VEGF drugs or long acting steroids. Only a small fraction of patients can be treated with current technology, and there are significant side effects such as internal bleeding, cataracts, retinal damage, increase of pressure inside the eye, and infection.

With the aid of Capsulution's formulation technology, TheraKine will bring an innovative drug-delivery system to the market. "We selected Capsulution because they have the right IP, skilled staff, and an entrepreneurial spirit.", explains TheraKine's CEO Scott Hampton. The collaboration with the internationally-renowned developer of nanocomplexes offers a promising advance towards the formulation of very easily degradable, water-soluble biologic compounds in combination with water-insoluble anti-inflammatory compounds or small molecules. According to Capsulution's Project CSO, Dr. Voigt: "For this application, controlled and sustained release of a pre-defined amount of compound is required." The compound depot in the biodegradable implant should, if possible, only be injected into the eye once.

Mr. Hampton declares: "TheraKine's mission is the creation of therapeutic system to improve vision and prevent blindness". He emphasizes the urgency of the situation: "Effective and safe treatments are desperately needed by millions of people who are currently suffering progressive vision loss due to chronic inflammatory and degenerative eye diseases. Our targeted local delivery will offer safety, effectiveness, and affordable treatment costs."

####

About Capsulution NanoScience AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company applies its worldwide-patented so-called LBL-Technology®. Based on their minute size, their functionality and their highly reproducible production process the tunable capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer.

About TheraKine:
TheraKine was founded in 2004 when a widely respected physician
discovered better treatments for children who were rapidly losing
their eyesight due to chronic inflammatory eye disease. Frustrated by
the limitations of existing systemic delivery systems, the TheraKine
team soon decided that a local, targeted approach to delivery would
produce a much more effective and efficient outcome for the patient.
This work continues, with exciting results in feasibility trials.
TheraKine estimates that the first human clinical trials will start
in the fourth quarter of 2009.

For more information, please click here

Contacts:
Herr Dipl.-Kfm. Alexander Herrmann

Telefon: +49 (30) 6706919-129
Fax: +49 (30) 6706919-101
Zuständigkeitsbereich: Chief Financial Officer (CFO)

Herr Jerry Seelig
TheraKine Ltd.

Telefon: +1 (678) 648-4037
Fax: +1 (678) 623-9550
Zuständigkeitsbereich: Senior Business Development

Copyright © Capsulution NanoScience AG

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Announcements

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Alliances/Trade associations/Partnerships/Distributorships

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

JPK Instruments announce partnership with Swiss company, Cytosurge AG. The partnership makes Cytosurge’s FluidFM® technology available on the JPK NanoWizard® AFM platform December 8th, 2017

Nano Global, Arm Collaborate on Artificial Intelligence Chip to Drive Health Revolution by Capturing and Analyzing Molecular Data in Real Time November 21st, 2017

EC Project Aims at Creating and Commercializing Cyber-Physical-System Solutions November 14th, 2017

Research partnerships

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Wheat gets boost from purified nanotubes: Rice University toxicity study shows plant growth enhanced by -- but only by -- purified nanotubes December 6th, 2017

Copper will replace toxic palladium and expensive platinum in the synthesis of medications: The effectiveness of copper nanoparticles as a catalyst has been proven December 5th, 2017

Researchers advance technique to detect ovarian cancer: Rice, MD Anderson use fluorescent carbon nanotube probes to achieve first in vivo success November 30th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project